Format

Send to

Choose Destination
Biomed Pharmacother. 2017 Jul;91:776-787. doi: 10.1016/j.biopha.2017.04.117. Epub 2017 May 10.

Adipose-derived mesenchymal stem cells slow disease progression of acute-on-chronic liver failure.

Author information

1
Department of General and Digestive Surgery, Sureste Hospital, Arganda del Rey, Madrid, Spain.
2
Department of Surgery, School of Medicine, Complutense University of Madrid, Madrid, Spain.
3
Cell Engineering Laboratory, La Paz University Hospital Biomedical Research Institute, IDiPAZ, Madrid, Spain.
4
Department of General and Digestive Surgery, La Paz University Hospital, Autonomous University of Madrid, Madrid, Spain.
5
Department of Plastic and Reconstructive Surgery, Santa Cristina Hospital and Centrocim, Madrid, Spain.
6
Department of Anesthesia and Resuscitation, Sureste Hospital, Arganda del Rey, Madrid, Spain.
7
Cell Engineering Laboratory, La Paz University Hospital Biomedical Research Institute, IDiPAZ, Madrid, Spain. Electronic address: mmiguelgonzalez@salud.madrid.org.

Abstract

A serious complication of chronic hepatic insufficiency is acute-on-chronic liver failure, a recognized syndrome characterized by acute decompensation of cirrhosis and organ/system failure. We investigated the use of adipose-derived mesenchymal stem cells (AD-MSCs) in an experimental model of acute-on-chronic liver failure, developed by microsurgical extrahepatic cholestasis in rats. Rats undergoing microsurgical extrahepatic cholestasis were treated by intraparenchymal liver injection of human or rat AD-MSCs, undifferentiated or previously differentiated in vitro toward the hepatocyte lineage. The groups treated with rat AD-MSCs showed less ascites, lower hepato- and splenomegaly, less testicular atrophy, and an improvement in serum biochemical hepatic parameters. There was also an improvement in histological liver changes, in which the area of fibrosis and bile duct proliferation were significantly decreased in the group treated with predifferentiated rat AD-MSCs. In conclusion, an isograft of hepatocyte-predifferentiated AD-MSCs injected intraparenchymally 2 weeks after microsurgery in extrahepatic cholestatic rats prevents secondary complications of acute-on-chronic hepatic failure. These data support the potential use of autologous AD-MSCs in the treatment of human cholestasis, and specifically of newborn biliary atresia, which could be beneficial for patients awaiting transplant.

KEYWORDS:

Adipose derived stem cells; Animal models; Cellular therapy; Liver regeneration; Mesenchymal stem cells

PMID:
28501004
DOI:
10.1016/j.biopha.2017.04.117
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center